GM.CD40L cell vaccine

Known as: GM.CD40L 
A cell-based vaccine composed of irradiated tumor cells transduced with granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40-ligand… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma
The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
A phase I/II randomized trial using GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine in combination with CCL21 in stage IV lung adenocarcinoma: Preliminary results.
 
Is this relevant?
2016
2016
Phase I/II randomized trial of GM.CD40L vaccine plus/minus CCL21 in advanced lung adenocarcinoma: Final results.
 
Is this relevant?
2008
2008
Ongoing Studies with GM.CD40L Bystander-Based Vaccines
Drs Kobayashi and colleagues are correct in pointing out that patient selection, sample size, heterogeneity of patient… (More)
Is this relevant?
2006
2006
A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV…
Significant antitumor T-cell responses are generated in vitro when human lymphocytes are stimulated with autologous tumor cells… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?